Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXL-1427 in Hospitalized Systolic Heart Failure
NCT02157506Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of cimlanod, sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at 30 days, Mean Time Averaged Change From Baseline in Adjudicated Pulmonary Capillary Wedge Pressure at 6 hours and 2 more. Started Jun 2014; status: completed.
02
Drugs
cimlanod
Beyond the preview
Go deeper on NCT02157506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157506.